Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?

The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective drugs with various mechanisms of action, including nintedanib, ramucirumab, nivolumab, pemb...

Descripción completa

Detalles Bibliográficos
Autor principal: Morabito, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815183/
https://www.ncbi.nlm.nih.gov/pubmed/29448944
http://dx.doi.org/10.1186/s12916-018-1011-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815183/
https://www.ncbi.nlm.nih.gov/pubmed/29448944
http://dx.doi.org/10.1186/s12916-018-1011-0

Ejemplares similares